{"id":146,"date":"2023-02-13T15:34:30","date_gmt":"2023-02-13T15:34:30","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=146"},"modified":"2023-02-13T15:40:21","modified_gmt":"2023-02-13T15:40:21","slug":"aphrodite","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=146","title":{"rendered":"Aphrodite"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

APHRODITE – A Phase II trial of higher radiotherapy dose in the eradication of early rectal cancer<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

APHRODITE is a randomised phase II trial investigating non-surgical management and organ preservation for patients with early rectal cancer who are either unsuitable for radical TME surgery, are likely to have difficulty managing a stoma, or who are suitable for radical TME surgery but have a strong preference for an attempt at organ preservation.<\/p>\n\n\n\n

The trial will investigate whether dose escalation (delivering a higher radiation dose to the primary tumour as an integrated \u201cboost\u201d) using intensity-modulated radiation therapy (IMRT) in this patient group can be used to attain a complete clinical response (cCR) at 6 months, with long term tumour control and avoidance of tumour-related morbidity. The cCR will be assessed and compared at 6 months between the treatment groups.<\/p>\n\n\n\n

The trial aims to recruit 104 patients randomised 1:2 to either the standard dose arm or the escalated dose arm. Both arms will a radical dose of 50.4Gy to the primary tumour and surrounding mesorectum using IMRT, as well as concurrent chemotherapy. Patients randomised to the escalated dose arm with receive a 62Gy boost to their primary tumour volume.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>Contact RTTQA for details on downloading benchmark case<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>Contact RTTQA for details on downloading benchmark case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective: first standard arm patient, first dose-escalation arm patient
\nRetrospective: selected patients
\n<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>STAR-TReC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact: <\/strong>aphroditeqa.enh-tr@nhs.net<\/em><\/a> <\/em> <\/p>\n\n\n\n

Chief investigators: <\/strong>Professor Simon Gollins (Clinical Oncologist, Royal Shrewsbury Hospital) & Dr Ane Appelt (Physicist, Leeds Institute of Medical Research at St James\u2019 University Hospital<\/em><\/p>\n\n\n\n

Co-RT Lead: <\/strong>Dr Mark Teo (Leeds Cancer Centre, St James\u2019s University Hospital)<\/em><\/p>\n\n\n\n

Sponsor: <\/strong>Yorkshire Cancer Research<\/em><\/p>\n\n\n\n

Funder:<\/strong> University of Leeds, <\/em>aphrodite@leeds.ac.uk<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

APHRODITE – A Phase II trial of higher radiotherapy dose in the eradication of early rectal cancer Trial summary: APHRODITE is a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-146","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=146"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/146\/revisions"}],"predecessor-version":[{"id":154,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/146\/revisions\/154"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}